<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39364271</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Changes in memory and cognition during the SARS-CoV-2 human challenge study.</ArticleTitle><Pagination><StartPage>102842</StartPage><MedlinePgn>102842</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102842</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2024.102842</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Patient-reported outcomes and cross-sectional evidence show an association between COVID-19 and persistent cognitive problems. The causal basis, longevity and domain specificity of this association is unclear due to population variability in baseline cognitive abilities, vulnerabilities, virus variants, vaccination status and treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Thirty-four young, healthy, seronegative volunteers were inoculated with Wildtype SARS-CoV-2 under prospectively controlled conditions. Volunteers completed daily physiological measurements and computerised cognitive tasks during quarantine and follow-up at 30, 90, 180, 270, and 360 days. Linear modelling examined differences between 'infected' and 'inoculated but uninfected' individuals. The main cognitive endpoint was the baseline corrected global cognitive composite score across the battery of tasks administered to the volunteers. Exploratory cognitive endpoints included baseline corrected scores from individual tasks. The study was registered on ClinicalTrials.gov with the identifier NCT04865237 and took place between March 2021 and July 2022.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Eighteen volunteers developed infection by qPCR criteria of sustained viral load, one without symptoms and the remainder with mild illness. Infected volunteers showed statistically lower baseline-corrected global composite cognitive scores than uninfected volunteers, both acutely and during follow up (mean difference over all time points = -0.8631, 95% CI = -1.3613, -0.3766) with significant main effect of group in repeated measures ANOVA (F (1,34) = 7.58, p = 0.009). Sensitivity analysis replicated this cross-group difference after controlling for community upper respiratory tract infection, task-learning, remdesivir treatment, baseline reference and model structure. Memory and executive function tasks showed the largest between-group differences. No volunteers reported persistent subjective cognitive symptoms.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">These results support larger cross sectional findings indicating that mild Wildtype SARS-CoV-2 infection can be followed by small changes in cognition and memory that persist for at least a year. The mechanistic basis and clinical implications of these small changes remain unclear.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">This study was funded through the UK Vaccine Taskforce of the Department for Business, Energy and Industrial Strategy (BEIS) of Her Majesty's Government. WT was funded by the EPSRC through the CDT for Neurotechnology Imperial College London.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trender</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellyer</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Killingley</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University College London Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalinova</LastName><ForeName>Mariya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HVIVO Services Ltd., London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Alex J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>HVIVO Services Ltd., London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catchpole</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>HVIVO Services Ltd., London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cambridge University Hospitals National Health Service Foundation Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Needham</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cambridge University Hospitals National Health Service Foundation Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thwaites</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampshire</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04865237</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Baseline corrected</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Human challenge study</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>AH is founder and director of Future Cognition Ltd and H2 Cognitive Designs, which develop custom cognitive assessment tasks and provide online assessment services respectively, primarily within the academic research sector. CC had funding to institution from the UK Vaccine Task Force and Wellcome Trust. DM had support for the present manuscript in the form of payments to the institution from the UKRI (UKRI, The COVID-19: Clinical Neuroscience Study (COVID-CNS) (Co-I) and UKRI. Convalescent plasma for COVID-19 patients (Co-I)), the Addenbrooke's Charitable Trust (COVID-19: understanding its long-term respiratory, cardiac and neuro-psychiatric sequelae and the determinants of adverse outcomes), the NIHR (NIHR Cambridge Biomedical Research Centre). They also received support unrelated to the current manuscript in the form of consultancy fees and research support from: Neurotrauma Sciences, Lantmannen AB, GlaxoSmithKline Ltd and PressuraNeuro Ltd. EN received a portion of their salary from Brain Research UK during the periods in question. PJH is Co-founder and director of H2 Cognitive Designs LTD, which markets online cognitive testing platforms for healthcare and research. In this role he receives Remuneration. RT received support for the present manuscript from UK Vaccine Taskforce of the Department of Business, Energy and Industrial Strategy of Her Majesty's Government (BEIS) and the Wellcome Trust (grant no. 224530/Z/21/Z). Also payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca. WT is employed by H2 Cognitive Designs LTD, which markets online cognitive testing platforms for healthcare and research. AJM is a holder of shares in hVIVO Ltd and an employee of hVivo Ltd. MK, GS, BK and APC have no declarations of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364271</ArticleId><ArticleId IdType="pmc">PMC11447363</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2024.102842</ArticleId><ArticleId IdType="pii">S2589-5370(24)00421-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Burden of Disease Long COVID Collaborators Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604–1615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Trender W., Chamberlain S.R., et al. Cognitive deficits in people who have recovered from COVID-19. eClinicalMedicine. 2021;0 doi: 10.1016/j.eclinm.2021.101044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101044</ArticleId><ArticleId IdType="pmc">PMC8298139</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Chatfield D.A., MPhil A.M., et al. Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort. eClinicalMedicine. 2022;47</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9048584</ArticleId><ArticleId IdType="pubmed">35505938</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H., Lu S., Chen J., et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020;129:98–102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324344</ArticleId><ArticleId IdType="pubmed">32912598</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., McAuley H., Harrison E.M., et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275–1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S., Shibata K., Hellyer P.J., et al. Rapid vigilance and episodic memory decrements in COVID-19 survivors. Brain Commun. 2022;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807287</ArticleId><ArticleId IdType="pubmed">35128398</ArticleId></ArticleIdList></Reference><Reference><Citation>Amalakanti S., Arepalli K.V.R., Jillella J.P. Cognitive assessment in asymptomatic COVID-19 subjects. VirusDisease. 2021;32:146–149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883942</ArticleId><ArticleId IdType="pubmed">33614860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.-H., Chen Y., Wang Q.-H., et al. One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol. 2022;79:509–517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905512</ArticleId><ArticleId IdType="pubmed">35258587</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Brutto O.H., Rumbea D.A., Recalde B.Y., Mera R.M. Cognitive sequelae of long COVID may not be permanent: a prospective study. Eur J Neurol. 2022;29:1218–1221.</Citation><ArticleIdList><ArticleId IdType="pubmed">34918425</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihlaja R.E., Kauhanen L.-L.S., Ollila H.S., et al. Associations of subjective and objective cognitive functioning after COVID-19: a six-month follow-up of ICU, ward, and home-isolated patients. Brain Behav Immun Health. 2023;27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812472</ArticleId><ArticleId IdType="pubmed">36624888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Azor A., Atchison C., et al. Cognition and memory after covid-19 in a large community sample. N Engl J Med. 2024;390:806–818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615803</ArticleId><ArticleId IdType="pubmed">38416429</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Brutto O.H., Wu S., Mera R.M., Costa A.F., Recalde B.Y., Issa N.P. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: a longitudinal prospective study nested to a population cohort. Eur J Neurol. 2021;28:3245–3253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014083</ArticleId><ArticleId IdType="pubmed">33576150</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheetham N.J., Penfold R., Giunchiglia V., et al. The effects of COVID-19 on cognitive performance in a community-based cohort: a COVID symptom study biobank prospective cohort study. eClinicalMedicine. 2023;62 doi: 10.1016/j.eclinm.2023.102086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102086</ArticleId><ArticleId IdType="pmc">PMC10466229</ArticleId><ArticleId IdType="pubmed">37654669</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G., Lee S., Alfaro-Almagro F., et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:1–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham E.J., Ren A.L., Digby R.J., et al. Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. Brain. 2022;145</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494359</ArticleId><ArticleId IdType="pubmed">36065116</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera J.A., Boutajangout A., Masurkar A.V., et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia. Alzheimers Dement. 2022;18:899–910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9011610</ArticleId><ArticleId IdType="pubmed">35023610</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Skorniewska Z., Hampshire A., et al. Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nat Med. 2023;29:1–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10579097</ArticleId><ArticleId IdType="pubmed">37653345</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan F.-Y., Filler R., Mathew S., et al. Sociodemographic risk factors for coronavirus disease 2019 (COVID-19) infection among Massachusetts healthcare workers: a retrospective cohort study. Infect Control Hosp Epidemiol. 2021;42:1473–1478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185417</ArticleId><ArticleId IdType="pubmed">33504372</ArticleId></ArticleIdList></Reference><Reference><Citation>Drefahl S., Wallace M., Mussino E., et al. A population-based cohort study of socio-demographic risk factors for COVID-19 deaths in Sweden. Nat Commun. 2020;11:5097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547672</ArticleId><ArticleId IdType="pubmed">33037218</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker J.H., Vannorsdall T.D., Weisenbach S.L. Evaluation of post–COVID-19 cognitive dysfunction: recommendations for researchers. JAMA Psychiatr. 2023 doi: 10.1001/jamapsychiatry.2023.2820. published online Aug 16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2023.2820</ArticleId><ArticleId IdType="pubmed">37585198</ArticleId></ArticleIdList></Reference><Reference><Citation>Killingley B., Mann A.J., Kalinova M., et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat Med. 2022;28:1031–1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">35361992</ArticleId></ArticleIdList></Reference><Reference><Citation>Soreq E., Leech R., Hampshire A. Dynamic network coding of working-memory domains and working-memory processes. Nat Commun. 2019;10:936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389921</ArticleId><ArticleId IdType="pubmed">30804436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Highfield R.R., Parkin B.L., Owen A.M. Fractionating human intelligence. Neuron. 2012;76:1225–1237.</Citation><ArticleIdList><ArticleId IdType="pubmed">23259956</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapeport G., Smith E., Gilbert A., Catchpole A., McShane H., Chiu C. SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic. N Engl J Med. 2021;385:961–964.</Citation><ArticleIdList><ArticleId IdType="pubmed">34289273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul M., Varatharaj A., Nicholson T.R., et al. Defining causality in COVID-19 and neurological disorders. J Neurol Neurosurg Psychiatry. 2020;91:811–812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299654</ArticleId><ArticleId IdType="pubmed">32503883</ArticleId></ArticleIdList></Reference><Reference><Citation>Miskowiak K.W., Pedersen J.K., Gunnarsson D.V., et al. Cognitive impairments among patients in a long-COVID clinic: prevalence, pattern and relation to illness severity, work function and quality of life. J Affect Disord. 2023;324:162–169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9795797</ArticleId><ArticleId IdType="pubmed">36586593</ArticleId></ArticleIdList></Reference><Reference><Citation>França T.F.A., Bitencourt A.M., Maximilla N.R., Barros D.M., Monserrat J.M. Hippocampal neurogenesis and pattern separation: a meta-analysis of behavioral data. Hippocampus. 2017;27:937–950.</Citation><ArticleIdList><ArticleId IdType="pubmed">28597491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellingjord-Dale M., Brunvoll S.H., Søraas A. Prospective memory assessment before and after Covid-19. N Engl J Med. 2024;390:863–865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11156183</ArticleId><ArticleId IdType="pubmed">38416436</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy-González M., Navarra-Ventura G., Gomà G., et al. Objective and subjective cognition in survivors of COVID-19 one year after ICU discharge: the role of demographic, clinical, and emotional factors. Crit Care. 2023;27:188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10184095</ArticleId><ArticleId IdType="pubmed">37189173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland A.R., Barraclough M., Trender W.R., et al. Profiles of objective and subjective cognitive function in Post-COVID Syndrome, COVID-19 recovered, and COVID-19 naïve individuals. Sci Rep. 2024;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11166972</ArticleId><ArticleId IdType="pubmed">38862569</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A.P. Twenty-five years of research on the behavioural malaise associated with influenza and the common cold. Psychoneuroendocrinology. 2013;38:744–751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130811</ArticleId><ArticleId IdType="pubmed">23021498</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>